WUXI BIOLOGICS ADR Aktie

 

Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased......

- Further demonstrates WuXi Biologics' Global Dual Sourcing strategy in commercial manufacturing - Underscores the excellence of WuXi Biologics' world-class quality system across its global network DUNDALK, Ireland, Aug. 18, 2025 /PRNewswire/ -- WuXi Biologics (Stock code: 2269.HK), a......

Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading......

WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stable platform maintains stable expression and consistent product quality during long-term......

Earns CDP's highest rating for supply chain engagement on climate Adds to other CDP recognition—Water Security A List and leadership score on climate change Drives sustainability through value chain decarbonization empowerment SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- WuXi Biologics......

At midday close, HSI dropped 108 pts or 0.4% to 25,415. HSTI dropped 88 pts or 1.6% to 5,555. HSCEI fell 39 pts or 0.4% to 9,106.Active Heavyweights:BABA (09988.HK) closed at $119.1, down 1.3%TENCENT (00700.HK) closed at $550.5, down 0.8%PING AN (02318.HK) closed at $56.85, up 0.8%MEITUAN (03690.HK) closed at $129.4, up 0.6%XIAO......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

At close, HSI dropped 37 pts or 0.1% to 25,524. HSTI dropped 19 pts or 0.3% to 5,644. HSCEI fell 31 pts or 0.3% to 9,145. Market turnover reached $267.01 billion.Active Heavyweights:XIAOMI (01810.HK) closed at $55.3, down 2.6%HKEX (00388.HK) closed at $440.8, down 1.9%CCB (00939.HK) closed at $8.19, down 1.8%MEITUAN (03690.HK) c......

Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance......

At midday close, HSI dropped 242 pts or 0.9% to 25,319. HSTI dropped 99 pts or 1.8% to 5,564. HSCEI fell 108 pts or 1.2% to 9,068.Active Heavyweights:XIAOMI (01810.HK) closed at $54.65, down 3.8%HKEX (00388.HK) closed at $438.4, down 2.4%CCB (00939.HK) closed at $8.19, down 1.8%MEITUAN (03690.HK) closed at $127.2, down 1.7%BABA ......

At close, HSI dropped 278 pts or 1.1% to 25,388. HSTI dropped 65 pts or 1.1% to 5,677. HSCEI fell 107 pts or 1.2% to 9,150. Market turnover reached $281.77 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $130.1, down 3.2%HKEX (00388.HK) closed at $435.8, down 2.8%BABA (09988.HK) closed at $118, down 1.9%XIAOMI (01810.HK......

At midday close, HSI dropped 284 pts or 1.1% to 25,383. HSTI dropped 97 pts or 1.7% to 5,645. HSCEI fell 116 pts or 1.3% to 9,140.Active Heavyweights:MEITUAN (03690.HK) closed at $131, down 2.5%XIAOMI (01810.HK) closed at $57.1, down 2.3%HKEX (00388.HK) closed at $438.4, down 2.2%BABA (09988.HK) closed at $117.7, down 2.2%TENCEN......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Citi predicted that leading Chinese pharma/ biopharma stocks would have a chance to beat expectations with their 1H25 results thanks to external licensing deals and strong growth in innovative drug sales. Meanwhile, leading Contract Development and Manufacturing Organizations (CDMOs) are also likely to deliver better-than-expect......

WUXI BIO (02269.HK) has issued a positive profit alert anticipating that its 1H25 revenue will increase by around 16% YoY; its GPM will expand by around 3.6% YoY; its profit and the profit attributable to its equity shareholders will increase by around 54% and around 56% YoY; and after adjusting for share-based compensation expe......

WuXi Biologics' pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-quality PFS solutions to clients worldwide Reinforces WuXi Biologics' strong track record of a 100% success rate passing PLIs across our......

Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading......

Market interest in China's healthcare sector, particularly in innovative drugs, picked up strongly since April 2025, suggesting that the contract sales organization (CXO) sector will attract more attention ahead of the summer reporting season, with the leaders benefiting from improving fundamentals, attractive valuations and......

DUNDALK, Ireland, June 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its Ireland site has been honored with the prestigious 2025 Operational Excellence in Life Sciences Award at......